Dermata Therapeutics Stock Net Income
| DRMA Stock | USD 0.36 0.02 5.88% |
Dermata Therapeutics fundamentals help investors to digest information that contributes to Dermata Therapeutics' financial success or failures. It also enables traders to predict the movement of Dermata Stock. The fundamental analysis module provides a way to measure Dermata Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Dermata Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -7.3 M | -7.7 M | |
| Net Loss | -8.6 M | -9.1 M | |
| Net Loss | -7.8 M | -8.2 M | |
| Net Loss | (2.67) | (2.80) | |
| Net Income Per E B T | 1.16 | 1.14 |
Dermata | Net Income |
Dermata Therapeutics Company Net Income Analysis
Dermata Therapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Dermata Therapeutics Net Income | (7.79 M) |
Most of Dermata Therapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Dermata Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Dermata Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Dermata Therapeutics is extremely important. It helps to project a fair market value of Dermata Stock properly, considering its historical fundamentals such as Net Income. Since Dermata Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Dermata Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Dermata Therapeutics' interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Dermata Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Dermata Therapeutics reported net income of (7.79 Million). This is 102.28% lower than that of the Biotechnology sector and 111.13% lower than that of the Health Care industry. The net income for all United States stocks is 101.37% higher than that of the company.
Dermata Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dermata Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Dermata Therapeutics could also be used in its relative valuation, which is a method of valuing Dermata Therapeutics by comparing valuation metrics of similar companies.Dermata Therapeutics is currently under evaluation in net income category among related companies.
Dermata Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Dermata Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Dermata Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Dermata Therapeutics' value.| Shares | Armistice Capital, Llc | 2023-12-31 | 218 K | Acadian Asset Management Llc | 2023-12-31 | 55.2 K | Virtu Financial Llc | 2023-12-31 | 13.5 K | Geode Capital Management, Llc | 2023-12-31 | 12.2 K | Tower Research Capital Llc | 2023-12-31 | 6.4 K | Wells Fargo & Co | 2023-12-31 | 703 | Susquehanna International Group, Llp | 2023-09-30 | 0.0 | Hcr Wealth Advisors | 2023-09-30 | 0.0 | Two Sigma Securities, Llc | 2023-12-31 | 0.0 | Ubs Group Ag | 2023-12-31 | 0.0 | Citadel Advisors Llc | 2023-09-30 | 0.0 |
Dermata Fundamentals
| Return On Equity | -1.26 | ||||
| Return On Asset | -0.67 | ||||
| Current Valuation | (5.1 M) | ||||
| Shares Outstanding | 6.66 M | ||||
| Shares Owned By Insiders | 3.84 % | ||||
| Shares Owned By Institutions | 6.18 % | ||||
| Number Of Shares Shorted | 101.77 K | ||||
| Price To Book | 0.43 X | ||||
| EBITDA | (8.04 M) | ||||
| Net Income | (7.79 M) | ||||
| Cash And Equivalents | 10.63 M | ||||
| Cash Per Share | 1.05 X | ||||
| Current Ratio | 8.07 X | ||||
| Book Value Per Share | 1.62 X | ||||
| Cash Flow From Operations | (6.41 M) | ||||
| Short Ratio | 1.17 X | ||||
| Earnings Per Share | (2.67) X | ||||
| Target Price | 1.5 | ||||
| Beta | 0.87 | ||||
| Market Capitalization | 2.26 M | ||||
| Total Asset | 7.98 M | ||||
| Retained Earnings | (53.39 M) | ||||
| Working Capital | 6.36 M | ||||
| Net Asset | 7.98 M |
About Dermata Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Dermata Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dermata Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dermata Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Dermata Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Dermata Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dermata Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Dermata Stock
| 0.73 | ELYM | Eliem Therapeutics | PairCorr |
| 0.53 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.53 | XFOR | X4 Pharmaceuticals Earnings Call This Week | PairCorr |
| 0.49 | NRSNW | NeuroSense Therapeutics | PairCorr |
| 0.47 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Dermata Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Dermata Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Dermata Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Dermata Therapeutics to buy it.
The correlation of Dermata Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Dermata Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Dermata Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Dermata Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Dermata Therapeutics Piotroski F Score and Dermata Therapeutics Altman Z Score analysis. For information on how to trade Dermata Stock refer to our How to Trade Dermata Stock guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Dermata Stock analysis
When running Dermata Therapeutics' price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |
Is Dermata Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dermata Therapeutics. If investors know Dermata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dermata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.67) | Return On Assets (0.67) | Return On Equity (1.26) |
The market value of Dermata Therapeutics is measured differently than its book value, which is the value of Dermata that is recorded on the company's balance sheet. Investors also form their own opinion of Dermata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dermata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dermata Therapeutics' market value can be influenced by many factors that don't directly affect Dermata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dermata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dermata Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dermata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.